The Effect of Percutaneous Radiofrequency Ablation of Feeding Arterial for Hepatocellular Carcinoma
The Clinical Value of Percutaneous Radiofrequency Ablation of Feeding Arterial for Hepatocellular Carcinoma
1 other identifier
interventional
120
1 country
1
Brief Summary
To evaluate a novel technique-ultrasound guided percutaneous abaltion of tumor feeding artery before RFA for liver malignancy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started May 2014
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 22, 2014
CompletedFirst Submitted
Initial submission to the registry
May 4, 2017
CompletedFirst Posted
Study publicly available on registry
May 8, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 31, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2018
CompletedOctober 17, 2018
October 1, 2018
3.9 years
May 4, 2017
October 16, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
completed tumor necrosis
Contrast enhanced CT or MRI was examed to evaluate tumor necrosis 1 month after ablation.
1 month
Secondary Outcomes (1)
tumor recurrence
up to 36 months
Study Arms (2)
PAFA and tumor ablation
EXPERIMENTALfirst percutaneous frequency ablation of tumor feeding artery and then ablation of tumor
tumor ablation
OTHERablation of tumor directly
Interventions
percutaneous ablation of tumor feeding artery
Eligibility Criteria
You may qualify if:
- tumor number ≤3， maximum tumor size ≤5cm;
- accessibility of tumors via a percutaneous approach;
- tumor feeding artery can be detected by 3D contrast enhance ultrasound;
- platelet count ≥ 50,000/ml and INR \<1.6;
- life expectancy more than 6 months
- Child grade A or B
You may not qualify if:
- patients who scheduled liver transplantation
- with extrahepatic metastasis
- women during menstruation, pregnancy, child birth and baby nursing period
- patients with severe mental disorder
- cardiopulmonary failure
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
Related Publications (1)
Zhang ZY, Lee JC, Yang W, Yan K, Wu W, Wang YJ, Chen MH. Percutaneous ablation of the tumor feeding artery for hypervascular hepatocellular carcinoma before tumor ablation. Int J Hyperthermia. 2018;35(1):133-139. doi: 10.1080/02656736.2018.1484525. Epub 2018 Jul 12.
PMID: 29999436DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Kun Yan, master
Peking University Cancer Hospital & Institute
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director of ultrasonography department
Study Record Dates
First Submitted
May 4, 2017
First Posted
May 8, 2017
Study Start
May 22, 2014
Primary Completion
March 31, 2018
Study Completion
December 1, 2018
Last Updated
October 17, 2018
Record last verified: 2018-10
Data Sharing
- IPD Sharing
- Will not share